eFFECTOR Therapeutics, Inc. (OTCPK: EFTR)
Health Care · Biotechnology · US
$0.00
+50.00% today · +50.0% 1Y
eFFECTOR Therapeutics, Inc. (OTCPK: EFTR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.41K and employs 14 people.
Over the last twelve months the share price has gained 50.0%, trading between 0.00 and 0.02.
Tweenvest scores eFFECTOR Therapeutics, Inc. across four factors: quality 6/100. Its strongest factor is quality.
EFTR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.41K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -12.42
- Dividend yield
- —
- Beta (5Y)
- 2.41
- 52-week high
- $0.02
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 4.70M
- Employees
- 14
- Next earnings
- —
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.
- ISIN
- US28202V2079
- Founded
- 2012
- Listed since
- Mar 1, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $260.95 | -1.82% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.16 | -0.02% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.22 | -0.29% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.30 | -1.23% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.72 | -6.99% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.